GLP-1 Drugs May Reduce Need for Emergency Care for Chronic Migraine

Preliminary study finds association between GLP-1 drug use and lower rates of ER visits, hospitalizations, and new migraine medication prescriptions.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

A preliminary study has found that people with chronic migraine who started taking glucagon-like peptide-1 (GLP-1) receptor agonist drugs for conditions like diabetes were approximately 10% less likely than those who started topiramate to visit the emergency department over the following year. They were also about 14% less likely to be hospitalized for any reason during that time. The study suggests GLP-1 drugs may help stabilize the disease burden of chronic migraine in ways not yet fully understood.

Why it matters

Chronic migraine is a debilitating condition that often requires emergency care and multiple preventive medications. Finding treatments that can reduce the need for these interventions could significantly improve quality of life for those living with chronic migraine.

The details

The observational study compared people with chronic migraine who started taking GLP-1 drugs like liraglutide, semaglutide, and exenatide for other conditions to those who started taking topiramate, a common migraine preventive medication. After accounting for factors like age, weight, and prior migraine treatments, the researchers found the GLP-1 group was less likely to visit the ER, be hospitalized, undergo nerve block procedures, or receive new prescriptions for migraine medications used to stop or prevent attacks.

  • The study data was analyzed in early 2026.
  • The findings will be presented at the American Academy of Neurology's 78th Annual Meeting in April 2026.

The players

Vitoria Acar, MD

Study author and researcher at the University of Sao Paulo in Brazil.

American Academy of Neurology

The leading professional association for neurologists and neuroscience professionals, hosting the annual meeting where the study findings will be presented.

Got photos? Submit your photos here. ›

What they’re saying

“People with chronic migraine often end up in the emergency room or they need to try several preventive medications before finding one that can work for them. Seeing these patterns of lower use of emergency care and lower use of drugs to stop migraines or trying additional drugs to prevent migraines among people taking GLP-1 drugs for other conditions suggests that these therapies may help stabilize the disease burden in ways that we haven't fully appreciated yet.”

— Vitoria Acar, MD, Study author (PRNewswire)

What’s next

Further studies are needed to determine if GLP-1 drugs directly cause the reduced need for emergency care and migraine medications, or if other unmeasured factors may play a role.

The takeaway

This preliminary research indicates GLP-1 drugs used for conditions like diabetes may provide unexpected benefits for those living with the debilitating effects of chronic migraine, potentially reducing reliance on emergency services and multiple migraine medications. More investigation is warranted to fully understand this association.